In line with these findings, we have previously reported that SGLT2 inhibitor, a glucose lowering drug, regulates NLRP3 inflammasome in macrophages by increasing serum BHB levels and lowering insulin levels in patients with type 2 diabetes mellitus (23). Here, NLRP3 is linked to type 2 diabetes mellitus.